Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Receivables data on record, last reported at $1.4 million in Q1 2025.

  • For Q1 2025, Receivables rose 0.8% year-over-year to $1.4 million; the TTM value through Mar 2025 reached $1.4 million, up 0.8%, while the annual FY2025 figure was $1.4 million, 0.8% up from the prior year.
  • Receivables reached $1.4 million in Q1 2025 per SXTC's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Receivables topped out at $1.8 million in Q1 2021 and bottomed at $1.2 million in Q1 2022.
  • Average Receivables over 5 years is $1.5 million, with a median of $1.4 million recorded in 2025.
  • Peak YoY movement for Receivables: plummeted 55.56% in 2021, then soared 36.54% in 2023.
  • A 5-year view of Receivables shows it stood at $1.8 million in 2021, then tumbled by 34.5% to $1.2 million in 2022, then skyrocketed by 36.54% to $1.6 million in 2023, then decreased by 11.22% to $1.4 million in 2024, then grew by 0.8% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $1.4 million in Q1 2025, $1.4 million in Q1 2024, and $1.6 million in Q1 2023.